The Myklebost group arranged a succesful workshop for the EU "Network of Excellence on Bone Tumours", Research Line 2: "Osteogenic tumours and related sarcomas", in which they are Work Package Leaders. Thirty participants from ten European countries - including several clinicians from the National Competence Centre for Sarcomas - discussed progress and plans during a two-day meeting held June 10-12th at Lysebu Conference Centre.
Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara Met al.(2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science, 379(6629), 253-260 DOI 10.1126/science.abj4784, PubMed 36656928
Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS(2022) Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines Front Oncol, 12, 1040730 DOI 10.3389/fonc.2022.1040730, PubMed 36523963
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RLet al.(2022) Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts Cancer Treat Rev, 112, 102491 DOI 10.1016/j.ctrv.2022.102491, PubMed 36502615